Fresh analysis indicates that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end conventional diet and exercise regimens.
Research printed in a prominent medical journal demonstrates that while overweight people often shed about a fifth of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these drugs must be cognizant of the risk of quick weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting mass in about one and a half years.
Comparing Therapies
The analysis, which reviewed dozens of studies involving thousands of participants, compared the results of these new drugs with conventional dieting.
Scientists point out that individuals who shed pounds through lifestyle changes alone generally experience a more gradual creep back—approximately 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Nutrition scientists suggest the mechanism of the injections is key to understanding the amplified weight return.
The injections copy a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement means appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
The NHS recommend the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of relapse, the therapy is often long-term.
This view is echoed by pharmaceutical companies, who note that the results "highlight the chronic character of obesity," akin to managing conditions like diabetes.
Patient Experiences
Individuals who have stopped the jabs describe a intense resurgence of cravings.
"It was like a switch flipping and you become ravenous," described an individual.
The struggle is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on integrated lifestyle management.
